Zobrazeno 1 - 1
of 1
pro vyhledávání: '"J. C. Baranda"'
Publikováno v:
Journal of Clinical Oncology. 29:546-546
546 Background: Drozitumab is a monoclonal antibody that triggers tumor cell apoptosis by selective agonistic interaction with the Apo2 ligand/TNF-related apoptosis-inducing ligand death receptor 5. This study assessed the safety of drozitumab combin